Celltrion Archives | Be Korea-savvy
Celltrion’s New Autoimmune Disease Treatment Zymfentra to Hit U.S. Market in Feb.

Celltrion’s New Autoimmune Disease Treatment Zymfentra to Hit U.S. Market in Feb.

SEOUL, Nov. 30 (Korea Bizwire) — Celltrion Healthcare Co. said Thursday its new autoimmune disease treatment, Zymfentra, will make its U.S. market debut on Feb. 29 next year. Zymfentra, a subcutaneous injection formulation of Celltrion’s infliximab Remsima, won approval from the U.S. Food and Drug Administration last month. The sales affiliate of South Korean pharmaceutical [...]

South Korean Listed Companies See First Sub-1 Trillion Won Stock Option Grants in Five Years

South Korean Listed Companies See First Sub-1 Trillion Won Stock Option Grants in Five Years

SEOUL, Nov. 30 (Korea Bizwire) – This year, the aggregate value of stock options granted by publicly listed companies in South Korea has dipped to 950 billion won, marking the first time in five years that it has fallen below the 1 trillion won threshold. The decline in the stock market has been a contributing factor, [...]

Celltrion’s New Autoimmune Disease Treatment Wins FDA Approval

Celltrion’s New Autoimmune Disease Treatment Wins FDA Approval

SEOUL, Oct. 23 (Korea Bizwire) — South Korea’s major pharmaceutical firm Celltrion Inc. said Monday its new autoimmune disease treatment has won approval from the U.S. Food and Drug Administration (FDA). The FDA approved Celltrion’s Zymfentra, a subcutaneous injection formulation of its infliximab Remsima, for maintenance therapy in adults with moderately to severely active ulcerative [...]

Shareholders of Both Celltrion, Celltrion Healthcare Approve Merger Plan

Shareholders of Both Celltrion, Celltrion Healthcare Approve Merger Plan

SEOUL, Oct. 23 (Korea Bizwire) — Shareholders of pharmaceutical firm Celltrion Inc. on Monday approved a plan to merge with its sales and marketing affiliate Celltrion Healthcare Co., company officials said. Celltrion Healthcare’s merger with Celltrion was also approved by the affiliate’s shareholders earlier in the day. The approval came about three months after Celltrion [...]

Celltrion Completes License Deal with J&J to Sell Autoimmune Biosimilar in U.S. in 2025

Celltrion Completes License Deal with J&J to Sell Autoimmune Biosimilar in U.S. in 2025

SEOUL, Aug. 25 (Korea Bizwire) — South Korea’s major pharmaceutical firm Celltrion Inc. said Friday it has completed a license deal with Johnson & Johnson to sell its autoimmune disease treatment biosimilar in the United States. The deal will allow Celltrion’s CT-P43, the company’s ustekinumab biosimilar referencing Stelara, developed by J&J’s pharmaceutical unit of Janssen [...]

Celltrion Signs Deal with U.S. Firm for Joint Research on Antibody Medication

Celltrion Signs Deal with U.S. Firm for Joint Research on Antibody Medication

SEOUL, Jan. 9 (Korea Bizwire) — South Korean biopharmaceutical firm Celltrion Inc. said Monday it has signed a contract with Rani Therapeutics, a U.S. bio firm, to cooperate in developing an oral antibody medication. RT-111 is Rani’s project to develop ustekinumab, sold under the name of Stelara by Janssen Pharmaceuticals for the treatment of Crohn’s [...]

Celltrion Receives Approval to Sell Anticancer Biosimilar Vegzelma in Japan

Celltrion Receives Approval to Sell Anticancer Biosimilar Vegzelma in Japan

SEOUL, Sept. 27 (Korea Bizwire) — South Korean biopharmaceutical firm Celltrion Inc. said Tuesday it has received approval to sell its anticancer biosimilar Vegzelma in Japan. According to the company, Japan’s Ministry of Health, Labor and Welfare recently approved the sale of the biosimilar, also known as CT-P16, which referenced Switzerland-based Roche Holding’s blockbuster pill [...]

Celltrion Partners with Abpro of U.S. for Breast Cancer Treatment Development

Celltrion Partners with Abpro of U.S. for Breast Cancer Treatment Development

SEOUL, Sept. 21 (Korea Bizwire) — South Korean biopharmaceutical firm Celltrion Inc. said Wednesday it has signed a deal to jointly develop a bispecific breast cancer treatment candidate of Abpro Corp. of the United States. Under the deal, Celltrion and Abpro will work together for the development and market release of breast cancer treatment candidate [...]

Celltrion Opens R&D Office in Boston to Focus on New Drug Development

Celltrion Opens R&D Office in Boston to Focus on New Drug Development

SEOUL, Aug. 22 (Korea Bizwire) — South Korean biopharmaceutical firm Celltrion Inc. has opened a research and development (R&D) office in Boston to help accelerate its new drug development capabilities in the United States, according to company officials Monday. Celltrion completed the establishment of the Boston R&D office earlier this year and hired local office [...]